A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Status:

Closed to Accrual

III

Phase

3rd

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

Nectin4

Investigational

Product

Enfortumab Vedotin

Antibody‒Drug Conjugate (i.v.)

Treatment Arms

o Arm A: Enfortumab Vedotin
Participants will receive enfortumab vedotin (EV) on days 1, 8 and 15 of each 28 day cycle.

o Arm B: chemotherapy
Participants will receive the assigned drug (docetaxel, vinflunine or paclitaxel) on day 1 of every 21 day cycle.